Compare Abbott Laboratories (ABT) vs F5 Inc (FFIV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs F5 Inc — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while F5 Inc trades at $418.92 (market cap $23.53B). The key difference: Abbott Laboratories is far larger — about 7.1× F5 Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while F5 Inc pays none. Which is the better fit depends on your goals.
| ABT | FFIV | |
|---|---|---|
Market Cap | $166.94B | $23.53B |
Sector | Health | Technology |
52-Week High | $136.62 | $424.18 |
52-Week Low | $82.57 | $223.99 |
Enterprise Value | $193.69B | $22.35B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
F5 (FFIV) trades at $417.11, up 2.16% on the day, reflecting strong momentum after three consecutive quarterly earnings beats. The stock is technically bullish, trading above key support levels, while fundamentals show robust revenue growth to $3.09B in 2025 and a high net income margin of 21.96%. Recent strategic moves include expanding AI security offerings through acquisitions and partnerships, positioning the company in the high-growth cybersecurity sector.
The outlook remains positive given consistent earnings outperformance and strategic focus on AI security, though valuation multiples like a P/E of 34.42 suggest premium pricing. Risks include competitive pressures and execution challenges in integrating new technologies. Analyst consensus is mixed with a $397 price target slightly below current levels, indicating cautious optimism amid growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →
